Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Incidence of infections in clinical trials of treatments for relapsed/refractory multiple myeloma: Systematic review and meta-analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

OOOmonefe O. OmofumaUniversity of South CarolinaYZYue ZhangYunnan UniversityCHChristian HamppRegeneron (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Omofuma et al. (2024) studied this question.

synapsesocial.com/papers/68e67069b6db6435875fb25bhttps://doi.org/10.1200/jco.2024.42.16_suppl.e19517
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world evidence on infection risk in multiple myeloma treated with BiTEs and CAR-T cells: a meta-analysis2026 · 1 citations
  2. 2Infection burden among patients with triple-class–exposed RRMM receiving non–T-cell–redirecting therapies: a US claims study2026
  3. 3Infection risk associated with teclistamab in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of clinical trial and real-world evidence2026 · 1 citations
  4. 4Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia2025 · 1 citations
  5. 5Incidence and risk factors for infections in the real-world setting in newly diagnosed myeloma patients treated with modern induction regimens2025